Michael Song, MD
Hematology & Oncology · San Antonio, TXNPI 1699262246
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $624 of the $724 with a category attached, or 86.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 26 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$127
- Genmab U.S., Inc.$125
- AstraZeneca$48
- Pfizer$44
- Tersera Therapeutics LLC$42
- Caris MPI, Inc.$40
- plus $297 from 14 others
Across 6 payments — averaging $10,687 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beone Medicines USA, Inc.$64K
- AbbVie$543
What the payments were for
- Food & beverage$62486%
- Education$10014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $127 |
| Genmab U.S., Inc. | 1 | $125 |
| AstraZeneca | 2 | $48 |
| Pfizer | 2 | $44 |
| Tersera Therapeutics LLC | 2 | $42 |
| Caris MPI, Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Cumberland Pharmaceuticals, Inc. | 1 | $32 |
| Merck | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Amgen | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPKINLY$125
How this compares
$724 in reported general payments places this provider in the 25th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.